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Abstract
Objective—HIV-infected people have elevated risk for some cancers. Changing incidence of 
these cancers over time may reflect changes in three factors: HIV population demographic 
structure (e.g. age distribution), general population (background) cancer rates, and HIV-associated 
relative risks. We assessed the contributions of these factors to time trends for 10 cancers during 
1996–2010.
Design—Population-based registry linkage study.
Methods—We applied Poisson models to data from the U.S. HIV/AIDS Cancer Match Study to 
estimate annual percent changes (APCs) in incidence rates of AIDS-defining cancers (ADCs: 
Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), and cervical cancer) and 7 non-AIDS-
defining cancers (NADCs). We evaluated HIV-infected cancer trends with and without adjustment 
for demographics, trends in background rates, and trends in standardized incidence ratios (SIRs, to 
capture relative risk).
Results—Cancer rates among HIV-infected people rose over time for anal (APC 3.8%), liver 
(8.5%), and prostate (9.8%) cancers, but declined for KS (1996–2000: −29.3%; 2000–2010: 
−7.8%), NHL (1996–2003: −15.7%; 2003–2010: −5.5%), cervical cancer (−11.1%), Hodgkin 
lymphoma (HL, −4.0%), and lung cancer (−2.8%). Breast and colorectal cancer incidence did not 
change over time. Based on comparison to adjusted models, changing demographics contributed to 
trends for KS and breast, colorectal, liver, lung, and prostate cancers (all p<0.01). Trends in 
background rates were notable for liver (APC 5.6%) and lung (−3.2%) cancers. SIRs declined for 
ADCs, HL (APC −3.2%), and lung cancer (−4.4%).
Conclusions—Demographic shifts influenced several cancer trends among HIV-infected 
individuals. Falling relative risks largely explained ADC declines, while background incidence 
contributed to some NADC trends.
Keywords
HIV/AIDS; cancer; statistical modeling; trends; United States
Corresponding author and requests for reprints: Hilary A. Robbins, 9609 Medical Center Drive, 6-E228, Bethesda, MD 20892, (240) 
276-7187, hilary.robbins@nih.gov. 
Conflicts of Interest: All authors declare no conflict of interest.
Author Contributions: Conception of study and study design: HAR, MSS, RMP, EAE. Statistical analyses: HAR, RMP. Interpretation 




AIDS. Author manuscript; available in PMC 2016 September 08.
Published in final edited form as:














People infected with human immunodeficiency virus (HIV) are at elevated risk for 
developing several cancers (1–3). Some of these malignancies are related to advanced 
immunodeficiency (i.e., acquired immunodeficiency syndrome or AIDS), and three are 
considered AIDS-defining cancers (ADCs, i.e., Kaposi sarcoma (KS), non-Hodgkin 
lymphoma (NHL), and cervical cancer) (4). Risk is also elevated for several non-AIDS-
defining cancers (NADCs), including lung cancer, Hodgkin lymphoma (HL), anal cancer, 
and liver cancer (1–3). The introduction of highly active antiretroviral therapy (HAART) in 
1996 was associated with dramatic declines in rates of KS and NHL (5;6). However, rates 
among people with HIV have increased for other cancers, such as anal and liver cancers 
(1;2;7–9).
It is useful to consider three broadly defined influences in assessing trends over time in 
cancer incidence rates within a subset of the general population (i.e., a subpopulation such as 
HIV-infected people). The first is changes in the demographic structure of the 
subpopulation. Since the widespread introduction of HAART and subsequent decline of 
AIDS-related mortality, the U.S. HIV population has aged substantially, and a growing 
number of people have survived more than 10 years since an AIDS diagnosis (10). Because 
risk for many cancers varies by age, other demographic characteristics, and degree or 
duration of immune suppression, these shifts may have led to changing cancer incidence 
over time.
Second, cancer incidence in a subpopulation is expected to change over time if there are 
changes in incidence in the underlying general population (i.e., changes in background 
rates). For example, population-wide changes in exposure to a cancer risk factor would be 
expected to affect cancer incidence both overall and in HIV-infected people.
Third, cancer incidence in a subpopulation would be expected to change with the relative 
risk of cancer for that subpopulation compared to the general population. Among HIV-
infected people, factors responsible for elevated cancer risk are complex and vary by cancer. 
They include elevated prevalence and poor immune control of oncogenic viruses (11), high 
prevalence of tobacco use (12), and differences in screening patterns between the HIV and 
general populations (13). Relative risks for cancer associated with HIV infection may 
change if, for example, antiretroviral treatment improves immune function or smoking 
prevalence among HIV-infected people declines faster than in the general population.
Though incidence of some cancers has changed over time among the U.S. HIV population, it 
is not known how these epidemiologic factors have contributed to trends. Systematic 
evaluation of these influences may aid understanding of past trends, as well as inform 
expectations of future trends in cancer incidence. In this study, we characterize trends in 
incidence of 10 cancers in the U.S. HIV population during 1996–2010. We then separately 
assess contributions to these trends of demographic shifts in the HIV population, changes in 
general population cancer incidence, and changes in the HIV-associated relative risk of 
cancer.
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The HIV/AIDS Cancer Match (HACM) Study links state HIV and cancer registries to 
identify cancers occurring in HIV-infected people (www.hivmatch.cancer.gov) (2). The 
present study utilizes HACM data from states and years where both name-based HIV 
reporting and cancer registry coverage are considered complete, including Colorado (1996–
2007), Connecticut (200292013;2010), Florida (1998–2002), Georgia (2004–2008), 
Michigan (1996–2010), New Jersey (1996–2007), and Texas (1997–2009) (person-time 
contributed by individual registries in each year is presented in Supplemental Digital 
Content 1). Individuals began follow-up at report of HIV infection or the beginning of data 
coverage, whichever came later, and exited follow-up at death or the end of data coverage, 
whichever came earlier. Multiple cancer diagnoses were allowed for a given individual, but 
for a given cancer site only the first diagnosis was included. Analyses were restricted to non-
Hispanic whites, non-Hispanic blacks, and Hispanics. The HACM Study was approved by 
institutional review boards, as required, at participating registries.
We used International Classification of Diseases for Oncology, 3rd Edition (ICD-O3) codes 
to identify cases of 10 cancers of interest in HIV-infected people. These cancers are 
associated with HIV infection or are otherwise common, and include KS, NHL, Hodgkin 
lymphoma, and cancers of the cervix, anus, female breast, colorectum, liver, lung, and 
prostate. Though only certain subtypes of NHL are considered ADCs, most NHL cases 
among HIV-infected people are the AIDS-defining subtypes (14); thus, we considered all 
NHLs together.
Statistical Analysis
For each cancer site, we used Joinpoint software (15) to identify change points in HIV-
infected cancer incidence rates among all registries combined during 1996–2010. Change 
points are years in which statistically significant changes occurred in the slope across yearly 
incidence rates (i.e., the annual percent change or APC). Then, we conducted separate 
analyses for time segments defined by any change points. To estimate time trends in HIV-
infected cancer incidence in each time segment, we used Poisson regression adjusted only 
for registry (referred to as “crude trends”). We tested for heterogeneity in trends between 
registries by adding an interaction term between calendar year and each registry, and 
additionally tested for heterogeneity in the adjusted trends described below. However, 
because we sought to describe overall trends, we did not include interaction terms in our 
main analyses.
To evaluate the contribution of changing HIV demographics, we further adjusted the crude 
Poisson models for age, sex, HIV risk group, race/ethnicity, and HIV/AIDS-relative time 
(“adjusted trends,” see Table 2 footnote for details). We assumed that changing demographic 
structure influenced HIV-infected trends for cancers where these adjusted trends differed 
from the crude trends, based upon a test of statistical significance that relied on a parametric 
bootstrap procedure. Specifically, for each bootstrap dataset (N=500), the counts in each cell 
were generated based on a Poisson distribution applied to the observed person-years, where 
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the Poisson mean was estimated from the adjusted model generated by the original dataset. 
We then separately fit the crude and adjusted models to the bootstrap data and computed the 
difference of the coefficients for calendar year. The empirical variance of this difference was 
used in a chi-square test of the null hypothesis that the difference between the crude and 
adjusted parameters is equal to zero. In a supplementary analysis, we aimed to attribute 
demographic contributions to individual demographic factors. We thus adjusted crude 
models separately for age, HIV risk group and sex, race/ethnicity, and HIV/AIDS-relative 
time, and used the resulting APCs to assess which factor(s) accounted for the difference in 
APCs between the crude and adjusted models.
To evaluate the contribution of changing background incidence, we assessed time trends in 
general population cancer incidence rates. We standardized these incidence rates from 
HACM cancer registries to the 2002 HIV population separately for each registry. Then, we 
estimated time trends in standardized general population incidence using linear regression 
models that accounted for the variability in the incidence rates and were additionally 
adjusted for registry. We did not perform this analysis for KS, because almost all KS cases in 
the general population occur among HIV-infected people (16).
The HIV-associated relative risk of cancer was captured using the standardized incidence 
ratio (SIR), which is the ratio of observed to expected cancer cases. We calculated expected 
counts using general population cancer rates in strata defined by year, registry, age, sex, and 
race/ethnicity. Expected counts for KS were based on 1973–1979 rates (16). We used 
Poisson regression to assess time trends in the SIRs, adjusted for demographic factors (see 
Table 2 footnote). Changing relative risk was assumed to influence HIV-infected trends if a 
significant trend was observed.
To illustrate trends, we graphically depict yearly incidence rates for each cancer in the HIV-
infected and general populations. These estimates are aggregated over registries, so they do 
not correspond directly to the statistical analyses which adjust for registry. Therefore, some 
significant trends in our main analyses may not be apparent in the figures. For HIV-infected 
people, we show crude incidence along with incidence standardized to the 2002 HIV 
population. Differences between the trends for these two rates in the HIV population support 
contributions of changing HIV demographics. For the general population, we present cancer 
incidence standardized to the 2002 HIV population, and changes in these rates over time 
imply contributions from changing background rates. The gap between the standardized 
HIV-infected rates and general population rates approximates the SIR, as we use a 
logarithmic scale.
We express time trends using APCs, calculated using the formula APC = exp(βyear) − 1 
where βyear is the coefficient for calendar year. We used a two-sided significance level of 
α=0.05 for statistical tests.
Results
We evaluated 275,975 HIV-infected people who contributed 1,471,866 person-years of 
follow-up during 1996–2010 (Table 1). Over this period, the proportion of follow-up time 
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contributed by individuals aged 50 or older increased from 13.0% (1996–2000) to 27.3% 
(2006–2010), illustrating a shift in age distribution that may have affected rates of some 
cancers. The population increasingly comprised individuals who had never been diagnosed 
with AIDS (an increase from 33.5% to 41.3% of person-time) and those surviving more than 
5 years after an AIDS diagnosis (from 17.5% to 38.4%). The distribution of person-time by 
HIV risk group, sex, and race/ethnicity did not change appreciably.
The number of HIV-infected cancer cases over follow-up ranged from 261 for female breast 
cancer to 2,437 for KS and 4,136 for NHL (Table 2). As indicated by SIRs (see Table, 
Supplemental Digital Content 2, which lists incidence rates and SIRs), risks were strongly 
elevated for KS, anal cancer, and NHL. Risk was not elevated for colorectal cancer and was 
lower among HIV-infected people than the general population for breast and prostate 
cancers. For some cancers, SIRs differed noticeably by time period; trends in SIRs (as a 
measure of risk relative to the general population) are analyzed formally below.
We show cancer incidence time trends from statistical analyses in Table 2, and graphical 
depictions in Figures 1 (ADCs) and 2 (NADCs). Change points for HIV-infected incidence 
rates were identified for KS in 2000 and for NHL in 2003, but not for other cancers; thus 
analyses for KS and NHL were separated into two time segments. In crude models, 
incidence in HIV-infected people increased over time for anal cancer (APC 3.8%, 95% CI 
1.4%, 6.2%), liver cancer (8.5%, 95% CI 4.6%, 12.5%), and prostate cancer (9.8%, 95% CI 
6.4%, 13.3%), and decreased for KS (1996–2000: APC −29.3%, 95% CI −32.9%, −25.5%; 
2000–2010: −7.8%, 95% CI −9.6%, −5.8%), NHL (1996–2003: −15.7%, 95% CI −17.3%, 
−14.0%; 2003–2010: −5.5%, 95% CI −7.8%, −3.0%), cervical cancer (−11.1%, 95% CI 
−14.3%, −7.7%), HL (−4.0%, 95% CI −6.5%, −1.4%), and lung cancer (−2.8%, 95% CI 
−4.5%, −1.1%) (Table 2). With the exception of HL, these changes over time are visible 
graphically as trends in crude incidence for the combined registries (trends in solid lines, 
Figures 1A–C, 2A, 2E–G). Breast and colorectal cancers showed no time trend. For anal 
cancer, crude trends were significantly heterogeneous (p<0.001) and appeared to differ 
qualitatively across registries (Figure, Supplemental Digital Content 3). This pattern was not 
apparent for other cancer sites. Results were similar for adjusted trends, although the 
heterogeneity in the anal cancer trend was somewhat attenuated (p=0.017, Figure, 
Supplemental Digital Content 3).
In comparison to these crude trends, time trends after adjustment for demographics were 
significantly weaker for KS (1996–2000: adjusted APC −25.6%, 95% CI −29.5%, −21.6%, 
p<0.001 for comparison with crude trend; 2000–2010: −5.7%, 95% CI −7.7%, −3.7%, 
p<0.001), liver cancer (6.6%, 95% CI 2.7%, 10.7%, p=0.006), and prostate cancer (2.9%, 
95% CI −0.3%, 6.3%, p<0.001) (Table 2). For lung cancer, the decreasing trend became 
stronger after adjustment (APC −6.8%, 95% CI −8.5%, −5.0%, p<0.001). For breast and 
colorectal cancers, adjusted trends differed significantly from crude trends (p<0.001 for 
both), but neither differed significantly from zero. For liver, lung, and prostate cancers, these 
differences in trends are visible graphically by comparison of crude and standardized HIV-
infected cancer incidence rates (comparison of solid and dashed lines, Figures 2E–G). In our 
supplementary analysis, adjustment only for age accounted for the difference in crude and 
adjusted APCs for breast, colorectal, liver, lung, and prostate cancers (see Table, 
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Supplemental Digital Content 4, which lists APCs adjusted for individual demographic 
factors). This implies that among various demographic shifts over time, aging specifically 
had the greatest influence on incidence rates of these cancers. For KS, on the other hand, 
adjustment for HIV/AIDS-relative time had the greatest impact.
Incidence in the general population increased over time for anal (APC 3.3%, 95% CI 1.4%, 
5.2%) and liver cancers (5.6%, 95% CI 4.6%, 6.6%), and decreased for NHL (2003–2010: 
−2.2%, 95% CI −3.3%, −1.0%) and cervical (−2.4%, 95% CI −3.4%, −1.3%), breast 
(−0.8%, 95% CI −1.2%, −0.5%), colorectal (−0.7%, 95% CI −1.1%, −0.3%), and lung 
(−3.2%, 95% CI −3.5%, −2.8%) cancers (Table 2). The directions of these trends were 
consistent with those in the HIV population, with the exception of breast and colorectal 
cancers which showed no significant trend in the HIV population. General population trends 
are visually evident for cervical, anal, liver, and lung cancers (solid lines with markers, 
Figures 1C, 2A, 2E, and 2F).
Decreasing SIRs contributed to trends over time for KS (1996–2000: APC −26.3%, 95% CI 
−30.2%, −22.3% and 2000–2010: −2.7%, 95% CI −4.8%, −0.7%), NHL (1996–2003: 
−14.5%, 95% CI −16.2%, −12.7% and 2003–2010: −4.0%, 95% CI −6.5%, −1.5%), cervical 
cancer (−9.4%, 95% CI −12.9%, −5.8%), HL (−3.2%, 95% CI −5.9%, −0.5%), and lung 
cancer (−4.4%, 95% CI −6.2%, −2.6%) (Table 2). Graphically, the declining magnitude of 
SIRs is visible as a decreasing gap over time between standardized incidence rates in the 
HIV-infected and general populations for NHL, cervical cancer, and lung cancer (decreasing 
gap between dashed lines and solid lines with markers, Figures 1B, 1C, and 2F).
Discussion
The incidence of many cancers changed over time in the U.S. HIV population during 1996–
2010, and these trends were variably influenced by demographic shifts in the HIV 
population, changing cancer rates in the general population, and changes in the HIV-
associated relative risk of cancer. In Table 3, we summarize these trends and the 
epidemiologic factors contributing to them. As we elaborate below, our results suggest that 
changes in demographics and in general population incidence rates were influential for most 
NADCs. In contrast, declines in ADCs were largely driven by decreasing relative risks.
Each ADC has a viral cause: human herpesvirus 8 for KS, Epstein-Barr virus (EBV) for a 
large fraction of NHLs, and human papillomavirus (HPV) for cervical cancer. Dramatic 
declines in KS and NHL have been attributed to improved immune control of oncogenic 
viruses with HIV treatment (5;6;17). Since 1996, clinical guidelines have recommended 
earlier HIV treatment, raising and finally eliminating the minimum CD4+ cell count 
threshold for treatment initiation (18–20). Further, during 2000–2008, HAART use 
increased in the U.S. HIV population (21). The falling SIRs that we observed for KS and 
NHL likely reflect this expanding uptake and increasing effectiveness of HAART. For 
cervical cancer, declining relative risk may reflect the effects of HAART on HPV infection 
(22;23) or perhaps improvements in cervical cancer screening among HIV-infected women.
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It has been suggested that aging and other demographic shifts in the HIV population are 
producing a rise in incidence of NADCs (8;10;11). Our results indicate this is true for some, 
though not all, of the cancers we studied. We found that demographic shifts contributed to 
increases in liver cancer, and they were the only factor contributing to the rise in prostate 
cancer. These demographic shifts also masked a more rapid decline in lung cancer that 
would have been observed if the population characteristics had not changed over time. For 
these NADCs, aging was the main factor influencing trends (see Table, Supplemental Digital 
Content 4). Adjustment for HIV/AIDS-relative time produced the largest change for KS (see 
Table, Supplemental Digital Content 4), due to lower KS risk among the increasing number 
of individuals surviving more than 5 years after an AIDS diagnosis (data not shown).
Time trends in general population incidence rates contributed to HIV-infected trends for 
several NADCs, specifically, for anal, breast, colorectal, liver, and lung cancers. Increasing 
liver cancer incidence in the U.S. general population has been attributed to long-term 
exposure to hepatitis B and C viruses (24), which have high prevalence in the HIV 
population (25). For lung cancer, declines in the general population are due to falling 
smoking prevalence (26), which may also be occurring in the HIV population. For breast 
and colorectal cancers, gradual decreases in the general population were countered by aging 
in the HIV population (Table 2, Supplemental Digital Content 4) leading to non-significant 
upward HIV-infected trends. Among ADCs, declines in the general population contributed 
to favorable NHL and cervical cancer trends, although changes in SIRs were likely more 
important.
Among NADCs, we observed decreasing trends in SIRs for lung cancer and HL. For lung 
cancer, this could reflect a faster decline in smoking prevalence in the HIV population than 
in the general population. Alternatively, the declining SIR may reflect benefits of HAART, 
since immune suppression and inflammation have been linked to development of lung 
cancer (12;27). For HL, previous studies (including some using data from the HACM Study) 
reported an increase or no change over time in incidence among HIV-infected people 
(1;2;10;28), but we observed a decline. This difference may be due to the addition of more 
recent data (through 2010) or the inclusion of large numbers of HIV-infected people who 
have not developed AIDS. HAART facilitates immune control of EBV, which contributes to 
the majority of HL cases among HIV-infected people (29).
Over 80% of anal cancers are caused by prolonged HPV infection (30), and HIV-infected 
people have nearly 30-fold increased anal cancer risk (31). According to our results, 
increasing anal cancer incidence among people with HIV was attributable to increasing 
background rates. However, because HIV-infected anal cancers have strongly influenced 
general population trends among men (32), the background trend we observed was likely 
affected by HIV-infected cases. If one were able to remove the HIV-infected cases, the 
general population trend would be flatter (32). Thus, we cannot exclude that the trend in the 
HIV population is actually due to a masked trend in relative risk. Further, we observed 
heterogeneity among registries for anal cancer. In additional analyses, the HIV-infected anal 
cancer trend was no longer significant upon removal of the New Jersey registry, which 
showed a robust upward trend (Figure, Supplemental Digital Content 3). We do not have an 
explanation for this heterogeneity, but its presence complicates understanding of the average 
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trends across registries. For these reasons, our results for anal cancer should be interpreted 
with caution.
Changes in cancer screening programs over time, including screening methods, 
recommendations, and public awareness, can influence cancer trends in complex ways that 
vary by cancer site. In our analysis, the observed impact of screening trends largely depends 
on how changes in screening compare between the HIV and general populations. 
Specifically, if screening among HIV-infected people increases over time for a cancer where 
screening reduces incidence (e.g., cervical cancer), then the HIV-infected incidence will 
show a downward trend. A general population contribution to this trend will be observed if 
the rate of screening uptake in the HIV population reflects the same uptake in the general 
population. If uptake is more rapid in the HIV population, then the relative difference will 
manifest as a decreasing SIR.
Strengths of our study include use of population-based data from seven U.S. states that cover 
most of the HAART era. We used a unique approach to evaluate complementary influences 
on cancer trends among HIV-infected people. One limitation is that our methodology may 
have failed to detect small contributions to these trends. For example, the lack of a 
significant p-value for a weak trend in the general population does not rule out that a trend in 
background incidence has affected the HIV population. While it would be ideal to explicitly 
decompose the crude trends into three components, our method does not allow us to quantify 
the relative contributions of the three factors to the crude trend. For instance, one should not 
expect the APCs for the general population and SIR to sum to either the adjusted or crude 
APC. As noted above, our data are derived from 7 different registries whose period of 
coverage is not homogeneous, though our analyses adjust for this limitation. Finally, we lack 
individual-level data describing HIV treatment, diagnosis or treatment of carcinogenic 
infections such as hepatitis B and C viruses, and cancer screening. Thus, we were unable to 
address these factors in our analyses.
In conclusion, our results indicate that the causes of recent trends in cancer incidence among 
HIV-infected people were multifaceted and differed by cancer site. HAART has reduced the 
incidence of many virus-related cancers by lowering the relative risk, and this result 
highlights the importance of continued improvement in accessible, early, and effective HIV 
treatment. However, for anal and liver cancers, the SIRs have not changed and incidence has 
increased. These adverse trends support efforts to make screening and prevention of these 
cancers a priority. For other cancers, especially prostate cancer, increasing incidence largely 
reflects the consequences of aging, and incidence should be expected to rise further as the 
HIV population continues to age.
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Figure 1. Incidence rates of AIDS-defining cancers in the U.S. HIV/AIDS Cancer Match Study, 
1996–2010
Solid and dashed lines depict crude and standardized incidence in the HIV population, 
respectively, and lines with triangle markers depict standardized incidence in the general 
population. Vertical dashed lines are displayed for years in which a Joinpoint was identified. 
In panel A, we do not show standardized incidence in the general population, because the 
majority of Kaposi sarcoma cases are in HIV-infected people (16). Rates are displayed on a 
logarithmic scale; note differing y-axis scales for individual panels. Panels are annotated 
with the relevant data substantiating the epidemiologic contributions to cancer trends listed 
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in Table 3. Abbreviations in annotations: APC, annual percent change; adj., adjusted; SIR, 
standardized incidence ratio; Gen.Pop., general population; comparison p, p-value for 
comparison between crude and adjusted HIV-infected trends.
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Solid and dashed lines depict crude and standardized incidence in the HIV population, 
respectively, and lines with triangle markers depict standardized incidence in the general 
population. Rates are displayed on a logarithmic scale; note differing y-axis scales for 
individual panels. Panels are annotated with the relevant data substantiating the 
epidemiologic contributions to cancer trends listed in Table 3. Abbreviations in annotations: 
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general population; comparison p, p-value for comparison between crude and adjusted HIV-
infected trends.
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Table 1








Total person-years with HIV 386,568 (100) 600,230 (100) 485,068 (100)
Age category
  0–14 6,527 (1.7) 7,268 (1.2) 3,402 (0.7)
  15–29 41,936 (10.8) 54,908 (9.1) 48,014 (9.9)
  30–39 156,209 (40.4) 187,179 (31.2) 112,404 (23.2)
  40–49 131,674 (34.1) 232,536 (38.7) 188,974 (39.0)
  50–59 38,770 (10.0) 93,123 (15.5) 102,588 (21.1)
  60–69 9,360 (2.4) 20,746 (3.5) 24,583 (5.1)
  70+ 2,092 (0.5) 4,471 (0.7) 5,103 (1.1)
Weighted mean age 39.0 41.3 43.1
Sex
  Male 284,691 (73.6) 439,063 (73.1) 361,716 (74.6)
  Female 101,876 (26.4) 161,167 (26.9) 123,352 (25.4)
HIV risk group
  MSM 167,172 (43.2) 258,282 (43.0) 220,898 (45.5)
  Non-MSM male IDU 56,146 (14.5) 75,005 (12.5) 51,925 (10.7)
  Male heterosexual 25,464 (6.6) 40,867 (6.8) 27,992 (5.8)
  Male other/unknown 35,910 (9.3) 64,909 (10.8) 60,901 (12.6)
  Female IDU 32,759 (8.5) 43,293 (7.2) 28,596 (5.9)
  Female heterosexual 47,346 (12.2) 77,348 (12.9) 55,232 (11.4)
  Female other/unknown 21,771 (5.6) 40,526 (6.8) 39,524 (8.1)
Race/ethnicity
  Non-Hispanic White 138,955 (35.9) 205,708 (34.3) 161,735 (33.3)
  Non-Hispanic Black 181,939 (47.1) 281,907 (47.0) 228,746 (47.2)
  Hispanic 65,674 (17.0) 112,616 (18.8) 94,587 (19.5)
HIV/AIDS-relative time
  HIV only 129,309 (33.5) 230,357 (38.4) 200,507 (41.3)
  1–24 months post AIDS 79,726 (20.6) 70,111 (11.7) 39,225 (8.1)
  25–60 months post AIDS 109,756 (28.4) 97,741 (16.3) 58,939 (12.2)
  61+ months post AIDS 67,776 (17.5) 202,022 (33.7) 186,398 (38.4)
Abbreviations: MSM, men who have sex with men; IDU, injection drug users MSM includes individuals who are both MSM and IDU. Estimates 
are based on 275,975 HIV-infected individuals from individual registries as follows: Colorado, 11,466; Connecticut, 12,645; Florida, 74,472; 
Georgia, 32,377; Michigan, 19,208; New Jersey, 46,786; Texas, 79,021.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Robbins et al. Page 18
Table 3













  1996–2000 Decreasing Yes Not assessed Yes
  2000–2010 Decreasing Yes Not assessed Yes
NHL
  1996–2003 Decreasing No No Yes
  2003–2010 Decreasing No Yes Yes
Cervix Decreasing No Yes Yes
Anus Increasing No Yes No
Female breast No change Yes Yes No
Colorectum No change Yes Yes No
HL Decreasing No No Yes
Liver Increasing Yes Yes No
Lung Decreasing Yes Yes Yes
Prostate Increasing Yes No No
Abbreviations: KS, Kaposi sarcoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; SIR, standardized incidence ratio
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